Press coverage about ConforMIS (NASDAQ:CFMS) has been trending somewhat negative recently, Alpha One Sentiment Analysis reports. Alpha One, a division of Accern, identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ConforMIS earned a news impact score of -0.12 on Alpha One’s scale. Alpha One also assigned media headlines about the medical instruments supplier an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted AlphaOne’s rankings:

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

CFMS has been the topic of several recent analyst reports. Zacks Investment Research downgraded ConforMIS from a “hold” rating to a “sell” rating in a research report on Monday, March 6th. Canaccord Genuity set a $8.00 target price on ConforMIS and gave the stock a “hold” rating in a research report on Thursday, May 11th. Oppenheimer Holdings, Inc. set a $9.00 target price on ConforMIS and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Finally, B. Riley reiterated a “buy” rating and set a $7.50 target price on shares of ConforMIS in a research report on Tuesday, February 21st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $9.88.

ConforMIS (NASDAQ CFMS) traded down 1.90% during midday trading on Friday, hitting $4.12. The stock had a trading volume of 835,093 shares. The company’s 50-day moving average price is $4.73 and its 200 day moving average price is $6.38. The stock’s market cap is $180.66 million. ConforMIS has a 12-month low of $3.89 and a 12-month high of $10.93.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.04. ConforMIS had a negative return on equity of 60.57% and a negative net margin of 74.55%. The company had revenue of $20.50 million during the quarter, compared to analyst estimates of $18.48 million. During the same period in the prior year, the firm earned ($0.37) EPS. ConforMIS’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities research analysts predict that ConforMIS will post ($1.44) earnings per share for the current fiscal year.

In related news, insider Daniel Steines sold 5,000 shares of the business’s stock in a transaction dated Wednesday, April 26th. The stock was sold at an average price of $5.54, for a total transaction of $27,700.00. Following the completion of the transaction, the insider now owns 190,745 shares of the company’s stock, valued at approximately $1,056,727.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.55% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “ConforMIS (CFMS) Receives Daily Media Impact Rating of -0.12” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.